BNT162b2 mRNA COVID-19 Aşısının Miyokardiyal Perfüzyon Üzerindeki Geç Dönem Etkilerinin Miyokardiyal Perfüzyon Sintigrafisi ile Değerlendirilmesi

MUSTAFA EROL , AHMET EREN ŞEN

  • MUSTAFA EROL: Necmettin Erbakan Üniversitesi Tıp Fakültesi
  • AHMET EREN ŞEN: Necmettin Erbakan Üniversitesi Tıp Fakültesi
  • Year : 2026
  • Vol : 42
  • Issue : 2
  •  Page : 113-118
Amaç: Bu çalışma, miyokard perfüzyon sintigrafisi (MPS) kullanarak BNT162b2 mRNA COVID-19 aşısının miyokard perfüzyonu üzerindeki geç dönem etkilerini araştırmayı amaçlamıştır. Gereç ve Yöntemler: Eylül 2020 ile Eylül 2023 tarihleri arasında 18-70 yaş arası katılımcılarda farmakolojik stres ve istirahat tek foton emisyon bilgisayarlı tomografi (SPECT) MPS içeren 181 hasta üzerinde retrospektif bir analiz gerçekleştirilmiştir. Katılımcılar iki gruba ayrılmıştır: BNT162b2 mRNA aşısı olanlar (n=93) ve olmayanlar (n=88). Önceden kalp cerrahisi geçirmiş, şiddetli kalp kapak hastalığı, atriyal fibrilasyon veya miyokardiyal fonksiyonu etkileyen diğer önemli komorbiditeleri olan bireyler çalışma dışı bırakıldı. Demografik veriler, kardiyovasküler risk faktörleri ve MPS parametreleri (diyastol sonu hacmi [EDV], sistol sonu hacmi [ESV], ejeksiyon fraksiyonu [EF], toplam stres skoru [SSS]) gruplar arasında karşılaştırıldı. Bulgular: Yaş, cinsiyet veya kardiyovasküler risk faktörlerinde gruplar arasında anlamlı bir fark gözlenmedi (p > 0,05). Ortalama SSS, aşılananlarda 2,54 ± 3,69 ve aşılanmayanlarda 2,78 ± 4,15 idi (p = 0,453). Aşılanan ve aşılanmayan gruplar arasındaki ortalama EF değerleri sırasıyla %64,27 ± 7,85 ve %62,16 ± 9,79 idi (p = 0,11). EDV (74,91 ± 18,63 ml vs. 77,18 ± 23,66 ml; p = 0,48) ve ESV (27,58 ± 11,24 ml vs. 30,65 ± 15,69 ml; p = 0,14) arasında anlamlı bir fark gözlenmedi. Aşılanan ve aşılanmayan gruplar arasında iskemik MPS bulgularının sıklığı açısından istatistiksel olarak anlamlı bir fark bulunmamıştır (34% vs. 35%; p = 0,89). Sonuç: BNT162b2 mRNA aşısının geç dönemde miyokardiyal perfüzyon veya sol ventrikül fonksiyonu üzerinde herhangi bir olumsuz etkisi tespit edilmemiştir.
Cite this Article As : Erol M, Sen AE. Evaluation of Late-Term Effects of BNT162b2 mRNA COVID-19 Vaccine on Myocardial Perfusion by Myocardial Perfusion Scintigraphy. Selcuk Med J 2026;42(2): 113-118

Download Citation: Endnote/Zotero/Mendeley (RIS) RIS File

Download Citation: BibTeX BibTeX File

Conflict of interest : The authors declare that they have no conflict of interest.
This article is published under the CC BY-NC 4.0 license.
Selcuk Medical Journal
2026, Vol. 42 (2)
ISSN: 1017-6616
E-ISSN: 2149-8059
Received : , Accepted : , Published Online :

References

  1. 1. World Health Organization. Coronavirus Disease 2019 (Covid-19) Situation Report-51. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse /situation-reports/20200311-sitrep-51-Covid-19.pdf. Accessed 28 Jan 2021.
  2. 2. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA Covid-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices — United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977-82. doi: 10.15585/mmwr.mm7027e2
  3. 3. Dickey JB, Albert E, Badr M, et al. A series of patients with myocarditis following SARS-CoV-2 vaccination with mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging. 2021;14(8):1862-63. doi: 10.1016/j.jcmg.2021.06.003
  4. 4. Shaw KE, Cavalcante JL, Han BK, et al. Possible association between Covid-19 vaccine and myocarditis: clinical and CMR findings. JACC Cardiovasc Imaging. 2021;14(9):1856-61. doi: 10.1016/j.jcmg.2021.06.002
  5. 5. Correction: Reports of myocarditis and pericarditis following mRNA Covid-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature. BMJ Open. 2022;12(7):e059223corr1. doi: 10.1136/bmjopen-2021-059223corr1
  6. 6. Kaur RJ, Dutta S, Charan J, et al. Cardiovascular adverse events reported from Covid-19 vaccines: a study based on WHO database. Int J Gen Med. 2021;14:3909-27. doi: 10.2147/IJGM.S324349
  7. 7. Simone A, Herald J, Chen A, et al. Acute myocarditis following Covid‐19 mRNA vaccination in adults aged 18 years or older. JAMA Intern Med. 2021;181(12):1668‐70.doi: 10.1001/jamainternmed.2021.5511
  8. 8. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. 2021;385(23):2132–39.doi: 10.1056/NEJMoa2110737
  9. 9. Yasmin F, Najeeb H, Naeem U, et al. Adverse events following Covid -19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun Inflamm Dis. 2023;11(3):e807. doi: 10.1002/iid3.807
  10. 10. Nappi C, Megna R, Acampa W, et al. Effects of the Covid-19 pandemic on myocardial perfusion imaging for ischemic heart disease. Eur J Nucl Med Mol Imaging. 2021;48(2):421–27. doi: 10.1007/s00259-020-04994-6
  11. 11. Verberne HJ, Acampa W, Anagnostopoulos C, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging. 2015;42(12):1929-40. doi: 10.1007/s00259-015-3139-x
  12. 12. Germano G, Kavanaugh PB, Waechter P, et al. A new algorithm for the quantitation of myocardial perfusion SPECT. I: technical principles and reproducibility. J Nucl Cardiol. 2000;7(4):312-18. doi: 10.1067/mnc.2000.107766
  13. 13. Erol M, Tezcan H, Duran M, et al. The role of myocardial perfusion imaging in predicting myocardial ischemia in patients diagnosed with long Covid. Int J Cardiovasc Imaging. 2023;39(12):2279-84. doi: 10.1007/s10554-023-02928-5
  14. 14. Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, et al. A focused review on technologies, mechanisms, safety, and efficacy of available Covid-19 vaccines. Int Immunopharmacol. 2021;100:108162.doi: 10.1016/j.intimp.2021.108162
  15. 15. Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of Covid-19 vaccines: a rapid review. BMC Med. 2021;19(1):173. doi: 10.1186/s12916-021-02059-5
  16. 16. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–90. doi: 10.1056/NEJMoa2110475
  17. 17. Fraiman J, Erviti J, Jones M, et al. Serious adverse events of special interest following mRNA Covid-19 vaccination in randomized trials in adults. Vaccine. 2022;40(40):5798–05.doi: 10.1016/j.vaccine.2022.08.036
  18. 18. Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–00.doi: 10.1093/cvr/cvaa078
  19. 19. Buoninfante A, Andeweg A, Genov G, et al. Myocarditis associated with Covid-19 vaccination. npj Vaccines. 2024;9(1):122. doi: 10.1038/s41541-024-00893-1
  20. 20. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with Covid-19 mRNA vaccines. Circulation. 2021;144(6):471–84.doi: 10.1161/CIRCULATIONAHA.121.056135
  21. 21. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385(23):2140-49. doi: 10.1056/NEJMoa2109730
  22. 22. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. doi: 10.1056/NEJMoa2034577
  23. 23. Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620-36. doi: 10.1161/CIRCRESAHA.115.306301
  24. 24. Deng H, Tang TX, Chen D, et al. Endothelial dysfunction and SARS-CoV-2 infection: association and therapeutic strategies. Pathogens. 2021;10(5):582.doi: 10.3390/pathogens10050582
  25. 25. Marchio P, Guerra-Ojeda S, Vila JM, et al. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxid Med Cell Longev. 2019;2019:8563845.doi: 10.1155/2019/8563845
  26. 26. Maruhashi T, Soga J, Fujimura N, et al. Endothelial Dysfunction, Increased Arterial Stiffness, and Cardiovascular Risk Prediction in Patients With Coronary Artery Disease: FMD-J Study A. J Am Heart Assoc. 2018;7(14):e008588. doi: 10.1161/JAHA.118.008588
  27. 27. Lamprinou M, Sachinidis A, Stamoula E, et al. Covid-19 vaccines adverse events: potential molecular mechanisms. Immunol Res. 2023;71(3):356-72.doi: 10.1007/s12026-023-09357-5
  28. 28. Yamaji T, Harada T, Hashimoto Y, et al. Effects of BNT162b2 mRNA Covid-19 vaccine on vascular function. PLoS One. 2024;19(4):e0302512.doi: 10.1371/journal.pone.0302512
  29. 29. Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. 2023;8(6):595-05.doi: 10.1001/jamacardio.2022.0583
  30. 30. Patone, M., Mei, X. W., Handunnetthi, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with Covid-19 vaccination or SARS-CoV-2 infection. Nature medicine. 2022;28(2);410–22. doi:10.1038/s41591-021-01630-0
  31. 31. Fronza M, Thavendiranathan P, Chan V, et al. Cardiac magnetic resonance findings in asymptomatic individuals after mRNA Covid-19 vaccination: a cohort study. JACC Cardiovasc Imaging. 2024;17(3):321-30.doi: 10.1148/radiol.212559
Distribution of Summed Stress Scores among vaccinated and unvaccinated participants.
Distribution of Summed Stress Scores among vaccinated and unvaccinated participants.